Efficacy and safety of BeEAM regimen in pretreatment of autologous hematopoietic stem cell transplantation for patients with lymphoma
10.3760/cma.j.cn115356-20210607-00139
- VernacularTitle:BeEAM方案用于淋巴瘤患者自体造血干细胞移植预处理的效果及安全性
- Author:
Qingfen LI
1
;
Qike ZHANG
;
Jisheng ZHAO
;
Xiaofang WEI
;
Youfan FENG
;
Xiujuan HUANG
;
Yuan FU
Author Information
1. 甘肃省人民医院血液科，兰州 730000
- Keywords:
Lymphoma;
Pretreatment scheme;
Autologous hematopoietic stem cell transplantation;
BeEAM regimen
- From:
Journal of Leukemia & Lymphoma
2022;31(5):278-281
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of BeEAM (bendamustine+cytarabine+etoposide+melphalan) regimen in pretreatment of autologous hematopoietic stem cell transplantation for patients with lymphoma.Methods:The clinical data of 15 patients with lymphoma who underwent autologous hematopoietic stem cell transplantation after pretreatment with BeEAM regimen from January 2020 to February 2021 in Gansu Provincial Hospital were retrospectively analyzed. The transplant-related adverse reactions and hematopoietic reconstitution were evaluated.Results:During the pretreatment process of 15 patients, 13 patients had gastrointestinal adverse reactions such as nausea, vomiting and diarrhea, 2 patients had hypokalemia, and 1 patient had abnormal liver function, but all of them were grade 1-2, and no grade 3-4 adverse reactions occurred. One patient had poor platelet implantation, and the remaining 14 patients all achieved hematopoietic reconstruction. After transplantation, the median time of peripheral blood neutrophils and platelets good implantation in patients was 10 d (9-14 d) and 11 d (9-17 d), respectively. Until March 2021, all patients were alive during follow-up.Conclusions:The efficacy of BeEAM regimen in pretreatment of autologous hematopoietic stem cell transplantation for patients with lymphoma is good, and the adverse reactions are tolerable.
